Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate.
Four hemodialysis patients with transfusional iron overload were treated with three times weekly intravenous (IV) deferoxamine mesylate during the dialysis treatment. Using a gamma ray scattering technique, significant reductions in liver iron content were documented, with a mean follow-up of 20 months. Three of the four patients showed significant improvements in liver enzymes. This decrease in liver iron content could not be predicted by clinical parameters or serum ferritin. Therapy proved to be safe and effective, but follow-up requires monitoring of tissue iron by means other than standard laboratory tests.
Mossey
R T
RT
Department of Medicine, North Shore University Hospital, Manhasset, New York 11030.
Wielopolski
L
L
Bellucci
A G
AG
Wilkes
B M
BM
Chandra
M
M
D000328:Adult; D000410:Alanine Transaminase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D003676:Deferoxamine / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000378:metabolism* / Q000506:poisoning; D008099:Liver / Q000378:metabolism*; D006435:Renal Dialysis; D065227:Transfusion Reaction
D005293:Ferritins; D007501:Iron; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D003676:Deferoxamine